It is very important to establish the relationship among gene mutations, treatment, and prognosis, especially for driver or key genes, since this may suggest targets for more effective drugs in clinical practice such as EGFR in lung cancer (66) and KIT in gastrointestinal stromal tumors (67). This evidence concerns the gene KIT and lung cancer.